1865-11-8

Basic information

• Product Name: 2-Quinoxalinecarboxylic acid methyl ester
• Synonyms: 2-Quinoxalinecarboxylic acid methyl ester;-Quinoxalinecarboxylic acid Methyl ester;Methyl quinoxaline-2-carboxylate;QCA-Methyl ester
• CAS NO: 1865-11-8
• Molecular Formula: C₁₀H₈N₂O₂
• Molecular Weight: 188.18272
• Mol File: 1865-11-8.mol
• Article Data: 14

Chemical Properties

• Melting Point: 110-110.5 °C
• Boiling Point: 302.8±22.0 °C(Predicted)
• Appearance: /
• Density: 1.272±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Methanol (Sparingly)
• PKA: 0.22±0.30(Predicted)
• CAS DataBase Reference: 2-Quinoxalinecarboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Quinoxalinecarboxylic acid methyl ester(1865-11-8)
• EPA Substance Registry System: 2-Quinoxalinecarboxylic acid methyl ester(1865-11-8)

Safety Data

• Hazardous Substances Data: 1865-11-8(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 1865-11-8 differently. You can refer to the following data:
1. 2-Quinoxalinecarboxylic Acid Methyl Ester has been used as a reactant in the synthesis of quinoxaline derivatives that show antimycobacterial activity, while displaying minor activity itself. In addit ion to having the substructure that exhibits antitumor activity, it is also used in the design of guanine-guanine selective DNA cleaving agents.
2. 2-Quinoxalinecarboxylic Acid Methyl Ester has been used as a reactant in the synthesis of quinoxaline derivatives that show antimycobacterial activity, while displaying minor activity itself. In addition to having the substructure that exhibits antitumor activity, it is also used in the design of guanine-guanine selective DNA cleaving agents.

Upstream product

• 186581-53-3 diazomethane 
• 879-65-2 quinoxaline-2-carboxylic acid 
• 74200-25-2 Methyl Quinoxaline-3-carboxylate 1-Oxide 
• 67-56-1 methanol 
• 1593-08-4 Quinoxaline-2-carboxaldehyde 
• 5660-34-4 quinoxaline-2,3-dicarboxylic acid anhydride 
• 494-21-3 2-furan-2-yl-quinoxaline 
• 54745-92-5 quinoxaline-2-carboxylic acid chloride 
• 819868-68-3 (4,5-dichloro-imidazol-1-yl)-quinoxalin-2-yl-acetonitrile 
• 819868-69-4 quinoxalin-2-yl-[1,2,4]triazol-1-yl-acetonitrile 
• 74-88-4 methyl iodide 
• 480-96-6 benzofurazan oxide 
• 2605-68-7 methyl 2-(triphenylphosphoranylidene)propionate 
• 110490-03-4 quinoxaline-2,3-dicarboxylic acid monomethyl ester 

Downstream Products

• 54571-06-1 quinoxaline-2-carbohydrazide 
• 7065-23-8 ethyl quinoxaline-2-carboxylate 
• 108047-48-9 6,7-dimethyl-furazano<3,4-b>quinoxaline 
• 108047-51-4 diethyl 7,8-dimethyl-pyrazino<2,3-b>quinoxaline-2,3-dicarboxylate 
• 791-28-6 Triphenylphosphine oxide 

Relevant articles and documents

Smaller is smarter in a new cobalt(II) imide: Intermolecular interactions involving pyrazine versus the larger aromatic quinoxaline

The synthesis of one symmetric and one non-symmetric ligand based on imide, quinoxaline and pyrazine moieties are reported. The symmetric ligand, N-(2-quinoxalylcarbonyl)-2-quinoxalinecarboxamide (Hquinoxquinox), is structurally characterised as Hquinoxquinox·d6DMSO. The non-symmetric ligand, N-(2-pyrazylcarbonyl)-2-quinoxalinecarboxamide (HLquinoxpz), was used to prepare the cobalt(II) complex [CoII(quinoxpz)2]·CH3OH, which was observed to remain high spin at 90 K. The structures of HLquinoxquinox·d6DMSO and [CoII(quinoxpz)2]·CH3OH are evaluated with regard to their potential to produce spin crossover (SCO) behaviour and for the construction of three-dimensional coordination polymers.

Sodium cyanoborohydride-mediated direct conversion of some heterocyclic aldehydes to esters

An exceptional oxidizing behavior of sodium cyanoborohydride is observed where electron-withdrawing heterocyclic aldehydes are directly converted to their corresponding esters on treatment of sodium cyanoborohydride in methanol. The spectral analysis and

Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives

A series of pyrazine and quinoxaline derivatives have been synthesized, and their activity against M. tuberculosis (Mtb) and Mycobacterium avium (MAC) are reported. The 4-acetoxy-benzyl ester of pyrazinoic acid and 4′-acetoxybenzyl 2-quinoxalinecarboxylate showed excellent activity against Mtb (MIC ranges of less than 1-6.25 μg/mL) but only modest activity against MAC (MICs of 4-32 μg/mL).

One-step direct conversion of heterocyelie aldehydes to esters

One-step direct conversion of a series of heteroeyelie aldehydes to heterocyclie esters is reported here by the use of thiamine hydrochloride as a catalyst in the absence of nitrogen atmosphere in a reasonably high yield. This method exclusively produces

HETEROCYCLIC COMPOUNDS

The present invention relates to compounds of the general formula (1) wherein the variables are defined as given in the description and claims. The invention further relates to uses of and to, processes and intermediates related to compounds of the general formula (I), wherein Q is wherein the substituents of I, Ia and Ib are as defined in description and claims.

Imidazole-containing condensed tricyclic compound and application thereof

The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.